Navigation Links
Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
Date:2/14/2008

NATICK, Mass., Feb. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Fluid Management and Venous Access businesses to Avista Capital Partners for $425 million in cash. The sale follows the definitive agreement announced on December 13, 2007.

The Company expects to record an after-tax gain of approximately $120 million during the first quarter of 2008 in connection with the transaction.

"The sale of the Fluid Management and Venous Access businesses completes our previously announced plans to divest five non-strategic businesses," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These divestitures -- together with our expense and head count reductions and business restructuring -- are helping to realign our cost structure and simplify our operating model. The positive impact of these efforts will help us achieve our overall goals of restoring profitable growth, increasing shareholder value and strengthening Boston Scientific for the future."

"I am very excited to work with this exceptional management team to build on the strong leadership positions that the Fluid Management and Venous Access businesses currently hold in the cardiology, radiology and oncology markets," said Ron Sparks, Chairman and Chief Executive Officer of the new company. "We look forward to leveraging these franchises' brands, manufacturing facilities, sales forces, R&D capabilities and new product pipelines to create a world- class, stand-alone medical device company."

Avista said financing for the transaction was arranged by GE Capital Corporation and RBS Greenwich Capital. Ropes & Gray LLP served as legal counsel and RBS Greenwich Capital served as financial advisor to Avista Capital Partners.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Avista Capital Partners is a leading private equity firm with offices in New York and Houston. Founded in 2005, Avista manages $2.0 billion in private equity capital. Avista's strategy is to make controlling or influential minority investments primarily in growth-oriented media, healthcare and energy companies. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information, visit http://www.avistacap.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our divestiture of non-strategic assets, our restructuring initiatives, our operational strategy, our financial performance and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS FOR BOSTON SCIENTIFIC: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

CONTACT FOR AVISTA: Diana Postemsky

212-521-4805

Kekst and Company


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/17/2017)... Plantation, FL (PRWEB) , ... February 17, 2017 ... ... protection services and financial planning assistance to families and business owners in the ... the LifeNet 4 Families organization. , For more than 30 years, LifeNet ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... highly regarded orthopedic surgeon, Dr. Raj, to their network through his work at ... Chemistry from Dalhousie University, and his medical degree from Canada’s prestigious International Baccalaureate ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
Breaking Medicine Technology: